In order to externalize the value of its services division, which represents 90% of its income, the company has decided to spin it off.
Suspended from trading since Thursday, the title of the service provider for the pharmaceutical industry Oncodesign soars when trading resumes on Monday, July 4. It climbed 52.67%, to 14 euros, almost in line with the price offered by the Eres IV fund of the Edmond de Rothschild galaxy for the takeover of 52.17% of the capital of Oncodesign Services. As part of its upcoming split, the group will separate into two separate legal entities, both listed on Euronext Growth: on the one hand, Oncodesign, which will retain the service activities, which account for 90% of the group’s revenues , on the other hand, Oncodesign Precision Medicine (OPM), which will combine biotech and artificial intelligence activities.
Arthaud & Associés’ valuation approach results in a valuation of 3.4 million euros for OPM, which, according to analysts, constitutes a low level given the portfolio of projects, including two drug candidates to come into clinical phase and the short-term payment of a milestone by the Servier laboratory as part of the LRRK2 program for the treatment of Parkinson’s disease.
Invest